Extract

Prevalence of diabetes mellitus (DM) in patients with tuberculosis is increasing and may negatively impact outcome in patients with active disease [1]. Gastrointestinal problems, including gastroparesis, may result in delayed drug absorption or malabsorption in patients with DM, which may cause suboptimal drug exposure and poor outcome [2]. Studies on the pharmacokinetics of the first-line anti-tuberculosis drugs in patients with DM yielded conflicting results on low drug exposure [3–7]. Moxifloxacin is a potent bactericidal drug against Mycobacterium tuberculosis and is key for the treatment of multidrug-resistant tuberculosis (MDR-TB) [8]. Moreover, moxifloxacin can be recommended for tuberculosis treatment in patients with monoresistance or intolerance to first-line drugs [9]. Recently, we reported on a patient with tuberculosis and DM in which moxifloxacin exposure was reduced [10].